Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, a-synuclein (SNCA) and leucine-rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCApositive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.
Introduction
Understanding human diseases at some level has to involve the root cause, or etiology, of that disease. In some cases this is simple; in an infectious disease a causative agent (virus, bacteria, or parasite) can be isolated and used to replicate the disease in a model organism, according to Koch's postulates. But many major diseases have no known cause and are therefore considered sporadic. How might we approach understanding a disease where we cannot identify a single causative agent? Without etiology, much of our work has to be descriptive, our models of the pathogenic mechanisms miss the deepest parts of causation, and our treatments are based on symptoms and not on mechanism.
One way to begin to understand sporadic diseases is to look for inherited diseases with which they share some pathologic features. By identifying specific biologic pathways in the genetic disease one might then be able to extrapolate back to the mysterious sporadic case. Although this may seem to be farfetched, there are examples of where it is starting to reach clinical testing. In Alzheimer's disease the theoretical idea that all cases share a common molecular pathway to neuropathology was named the amyloid cascade hypothesis by Hardy and Selkoe. (1) This has led to the development of drugs (2) and immunologic approaches (3) that are currently in clinical trials. A major advantage of looking for genetic factors for diseases compared to, e.g., environmental contributors is that there are defined ways to assign gene variants as pathogenic. For rare variants within families, a gene is causal if it is inherited in either a dominant or a recessive manner, and thus shows segregation with the trait of interest. These Mendelian variants often have strong effects on protein function. Gene variants can also be considered pathogenic if they show association with a given disease. This occurs at a population rather than a family level, and is when a given gene variant occurs at a different frequency in disease cases and controls. The effects of genetic risk factors tend to be subtler, raising or lowering lifetime risk of disease. Although this has traditionally been approached for one gene at a time, more recently genome-wide association studies have been used to identify all common genetic risk factors for a given disease and rank them based on the strength of the effect.
Here we will discuss Parkinson's disease (PD), where identification of genetic contributions has revolutionized our thinking about the disease process. We will focus on two genes that cause dominantly inherited disease that may be related to sporadic PD. We will also discuss data from genetic association studies, including genome-wide association studies, that support the idea that there are causal mechanistic relationships between different genetic variants. For a more complete picture of the genetics of PD and parkinsonism, including rare recessive forms that mimic part or all of the PD phenotype, the reader is directed to several recent reviews.
An abbreviated genetic neuropathology of Parkinson's disease
Parkinson's disease can be, perhaps simplistically, viewed as a disease of two parts. First, as in all neurodegenerative conditions, there is a loss of neurons in a variety of brain regions. In PD, we often think of a group of neurons in the substantia nigra pars compacta, part of the basal ganglia. Nigral neurons use the neurotransmitter dopamine to signal to the striatum, and are critical for the starting or stopping movement. They are also pigmented, containing a substance, neuromelanin, that allows them to be seen in sections from the brain post mortem without staining. The extent of neuron loss in advanced PD is so severe that the nigra becomes depigmented, and it is thought that substantial numbers of cells are lost by the time symptoms begin. Because these neurons are involved in movement, for most people with PD, movement problems (shaking, slowness of movement, stiffness, and unstable posture) are the first symptoms to be noted. This clinical outcome is termed parkinsonism.
The second neuropathologic event in PD relates to deposits of proteins in remaining neurons. Protein deposition is common to many neurodegenerative diseases, and is usually associated with decreased solubility and/or increased aggregation of the protein involved. For example, in Alzheimer's disease there are aggregates of the Ab peptide, a proteolytic fragment of the membrane protein amyloid precursor protein (APP), outside of neurons called plaques, and aggregated tau protein inside cells that forms tangles. For PD, the characteristic protein deposition is a Lewy body, predominantly made of a small protein called a-synuclein (SNCA) as well as other protein and lipids. Using SNCA as a marker reveals that many brain regions are involved in PD, and has allowed development of a scheme describing the pathology as the disease progresses. (7) Of the known genes for PD, dominant mutations in the genes for SNCA and leucine-rich repeat kinase 2 (LRRK2) stand out due to their potential importance in understanding the relationship between inherited and sporadic PD. Mutations in LRRK2 cause a parkinsonism syndrome clinically similar to sporadic PD, suggesting that inherited and non-inherited PD might share mechanisms. Interestingly, LRRK2 mutations account for between 1 and 30% of all PD cases in different populations, (8) again emphasizing how similar LRRK2 mutations are to typical PD. LRRK2 codes for a large, complex protein, which has attracted attention as a therapeutic target for PD. (9, 10) a-Synuclein is important because the protein is the major component of Lewy bodies and related pathology. (11) Mutations in the SNCA gene cause a syndrome that is similar to sporadic PD, although sometimes with earlier onset and a more aggressive course. (12) (13) (14) The amount of SNCA protein is important, as shown by multiplication mutations (15) (16) (17) and by association of common genetic variants around SNCA with PD. (18, 19) Critically, the majority of LRRK2 cases that have come to autopsy have SNCA-positive Lewy bodies in various brain regions. (20) This potentially links LRRK2 to SNCA pathology and again reinforces the link between genetic diseases and sporadic PD pathology. Although deposition of the protein tau is associated with Alzheimer's disease, microtubule-associated protein tau (MAPT) gene mutations cause frontotemporal dementia with parkinsonism. (21) Therefore, loss of neurons in the substantia nigra can be driven by tau. Importantly, MAPT has been nominated as a candidate for gene association with sporadic PD and was found to be a significant risk factor for sporadic PD in a genome-wide association study for PD. (19) Unlike SNCA, tau is not deposited as a pathologic protein in PD, and so the mechanism(s) underlying its contribution to sporadic PD are not clear. Initial data looking at the relationship between the gene variants that increase risk and expression of tau suggest that having more tau is detrimental. (19) If confirmed, this would mean that like SNCA, the normal human tau protein can contribute to neurodegeneration if there is too much of it. Collectively, these data identify three suspects that might play pathogenic roles in inherited and sporadic PD. We will next discuss what these gene products normally do in the central nervous system and how mutations are thought to affect normal function as this can be a first clue to understanding why mutations cause disease.
LRRK2 is an intracellular signaling molecule
Leucine-rich repeat kinase 2 is a 2527-amino-acid-long protein with a catalytic core region composed of the ROCO protein family (22) signature ROC-COR bidomain followed by a kinase domain (Fig. 1) . The ROC domain is named for Ras of complex proteins as it has some homology to small GTPases including Ras. The COR domain is characteristic of the ROCO protein family and is so named because it is C-terminal of ROC. The kinase domain is generally similar to other Ser/Thr-type protein kinases, although it is only close to the LRRK2 homolog, LRRK1, in humans. The catalytic core is flanked N-terminally by a leucine-rich repeat domain and C-terminally by a WD40 repeat domain. In its N-terminal region, LRRK2 displays a large number of unusual repeat sequences termed either LRRK2 or ARM/HEAT repeats (23) (24) (25) (Fig. 1 ). Pathogenic mutations are concentrated in the catalytic center of the protein, including R1441C/G/H in the ROC domain, Y1699C in the COR region, and G2019S and I2020T in the kinase domain. (26) There is evidence that the different regions of LRRK2 containing PD-associated mutations communicate with each other. LRRK2 self-interacts, (27, 28) exists predominantly in a dimeric conformation (29) (30) (31) and possesses kinase activity in the dimeric state. (31) Intramolecular interactions in the central
ROC-COR portion of LRRK2 occur within each monomer
Problems and paradigms J.-M. Taymans and M. R. Cookson chain and collectively contribute to dimer formation. The dimer of LRRK2 may include ROC:ROC interactions, (30, 32) but there are stronger ROC:COR interactions (29, 32) and there are COR:COR interactions in more distant homologs of LRRK2 in other species. (33) Additionally, both the N-and C-terminal domains of human LRRK2 have been shown to interact (30) and a deletion mutant of LRRK2 lacking the central ROC-COR domain retains the ability to dimerize. (29) Importantly, R1441, the site of three pathogenic substitutions, mediates part of the intramolecular interactions seen in LRRK2. (32) The equivalent residue to Y1699 in the COR domain of a prokaryotic protein is placed at the ROC:COR molecular interface. (33) Local interactions at the ROC:COR interface are disrupted by these mutations (29) and thus may subtly influence dimerization. If, as proposed, (34) dimerization regulates GTPase activity in complex proteins, then such interactions may be important in the regulation of normal function of LRRK2 and may provide a link between that function and the pathogenic effects of mutations. Unfortunately, the normal function of LRRK2 is not yet defined, but the presence of both a ROC/GTPase and a kinase domain suggests that it may play a role in intracellular signaling. Generally, GTPases act as molecular switches for other effector proteins and kinases are often outputs for signaling pathways. A widely discussed hypothesis is that the ROC domain in its GTP-bound state stimulates kinase activity (Fig. 2) . The presence of non-hydrolyzable GTP analogs enhances LRRK2 kinase activity, (35, 36) although the effect is quite modest and incubation with GDP does not completely block it. (36, 37) Pathogenic mutations in the ROC domain disrupt GTPase activity (38, 39) but do not consistently increase kinase activity. (37, (40) (41) (42) (43) These data suggest that a simple regulation of kinase by ROC does not explain how all mutations in LRRK2 cause PD. A limitation of the above data is that there is no currently accepted substrate for LRRK2. Proposed substrates of LRRK2 kinase activity include moesin, (43) eukaryotic initiation factor 4E-binding protein (4EBP) (44) or b-tubulin-2C, (45) but whether these are physiologic is unclear. In the case of moesin, LRRK2 is not rate-limiting for phosphorylation in cells, (46) although the phosphorylation state of ezrin-radixinmoesin proteins in neurite filopodia correlates to LRRK2 levels in mouse primary cultures. (47) LRRK2 has been reported to phosphorylate SNCA using crude cell extracts as source of kinase, (48) although purified LRRK2 does not phosphorylate SNCA. (49) Like many kinases, (50, 51) LRRK2
can phosphorylate itself in vitro, which is often used as a measure of activity in the absence of a known substrate. Interestingly, the majority of autophosphorylation sites in LRRK2 map to the ROC/GTPase domain. (52, 53) This implies that the kinase domain is regulatory to the ROC/GTPase domain, which would then be the major output (Fig. 2) . If the output signal of LRRK2 is related to the ROC domain, then a search for interaction partners of ROC in its GTP-bound form might reveal signaling pathways for LRRK2. Clues for the specificity of LRRK2 function may also come from comparative studies with its only paralog. LRRK1 and LRRK2 have similar domain arrangements and biochemical properties, although LRRK1 is not linked to PD. The major differences between LRRK1 and LRRK2 are at the N-terminal region, where LRRK2 has a large number of unique repeats, (23) (24) (25) as well as in the C-terminal region. (23) This suggests that LRRK1 has properties that are different from LRRK2, and that both proteins likely impact different signaling pathways. It would be extremely helpful to identify binding partners unique to LRRK2 by examining the N-terminal region. The above considerations suggest that the normal function of LRRK2 relates to cell signaling, although to which pathways and in which cell types is unclear. Mutations probably change the function of the central GTPase/kinase region of the protein, which then outputs by as yet unidentified interactors to cell signaling. a-Synuclein is a small protein ( Fig. 1) with three distinct regions. Towards the N-terminus are a series of repeats that have variations on the sequence KTEGV. In the center of the protein is the NAC region (for non-amyloid component of amyloid plaques, where the fragment was first isolated), which has hydrophobic properties. Finally, at the C-terminus is an acidic tail. The SNCA protein is unusual in that it is natively unfolded in solution in vitro. (54) This lack of structure leads to a conformational flexibility (55) that allows it, for example, to bind reversibly to lipid membranes. When bound to lipid vesicles, SNCA adopts a helical conformation with part of the helix in the lipid bilayer and the acidic C-terminal tail projecting out into the solvent. It is thought that lipid binding is important for the normal function of SNCA, and SNCA may have a role in vesicular function. In neurons, SNCA is loosely bound to membranes and dissociates rapidly after electrical stimulation. (56) Removing SNCA from neurons leads to a number of subtle changes in vesicles and/or in vesicle release. (57) (58) (59) (60) (61) Additionally, several sets of experiments show that manipulating SNCA levels changes lipid composition in the brain. (62) (63) (64) (65) Collectively, these results suggest that the role of SNCA in the brain is to influence lipid vesicles, although the exact mechanism(s) involved are not fully identified. Furthermore, as the synucleins are only found in vertebrates, SNCA cannot be absolutely required for neuronal function and thus plays a modulatory role in the central nervous system. Point mutations in SNCA map to the region of KTEGV repeats. Because the normal function of SNCA is unclear, it is difficult to say how mutations impact function. Since knockout mice do not develop parkinsonism and may be resistant to compounds that kill dopamine neurons, (66, 67) and because increased SNCA load causes PD, it is not likely that mutations cause disease through loss of normal function. Instead, the protein has some inherent property that can be exaggerated by point mutation or through increase in protein concentration. The most likely, but not definitive, candidate for this is that mutant protein has a higher tendency to aggregate, which will be discussed below in the section on toxic effects of SNCA. In contrast to SNCA and LRRK2, the function of tau is better defined as it is a microtubule-associated protein. (68) Tau plays important roles in maintaining axonal integrity and morphology. Point mutations in tau cause tauopathies by a combination of loss of the normal binding to microtubules and, as for SNCA, an increased tendency to aggregate once dissociated from microtubules. (68) How subtle increases in tau expression associated with sporadic PD would impact the function of axons is unclear but we predict a similarly subtle change in microtubule dynamics. These data show that the main functions of SNCA and tau probably relate to their ability to bind lipids and/or other proteins. Neither protein is absolutely required for neuronal function and both may have modulatory roles. Whether this relates to the subtlety of a disease like PD, with preferential effects in some neurons as patients age, is unclear but it is interesting that both of the biologic processes that are affected, synaptic function and microtubule-dependent axonal transport, are tasks that neurons specifically have to achieve. Figure 2 . Models of LRRK2 autoregulatory mechanism. Two possible models are shown. On the left is the most widely discussed model that GTP regulates kinase, on the right is an alternative idea, that kinase may be modulatory to GTPase function. In either case, dysregulation is thought to be associated with cell death.
LRRK2 mutations cause neuronal damage
Leucine-rich repeat kinase 2 mutations cause PD and cell loss in the substantia nigra has been found in all autopsied LRRK2-positive cases. These considerations suggest that LRRK2 mutations are sufficient to cause dopaminergic cell death in humans. However, individual LRRK2 cases show loss of neurons in the spinal cord associated with mild amyotrophy, (69) cortical pathology associated with dementia, (69, 70) or with psychosis where the anatomic substrate is unclear. (71) Therefore, nigral neurons are preferentially vulnerable to mutant LRRK2, although the lesion is not absolutely selective. However, LRRK2 is present only at low expression levels in the substantia nigra, while structures with extensive connections with the substantia nigra, such as the striatum, show high expression levels of LRRK2. (72) (73) (74) (75) These data suggest that it is possible that there are contributions from other cells. These results are based largely on in situ hybridization for mRNA; as well-validated antibodies for endogenous LRRK2
are not yet available (76) and these data may need to be revisited with better reagents. What then is the toxic mechanism caused by LRRK2 mutations? Several pieces of data link LRRK2 to cytoskeleton and neurite morphology. LRRK2 has been shown to interact with microtubules (77) and to phosphorylate b-tubulin 2C. (45) LRRK2 overexpression in transfected SHSY-5Y cells, (78) transfected mouse primary cortical neurons (79) or transgenic mouse primary neuron cultures (47, 80) leads to reduced neurite outgrowth. While these effects may partially reflect decreased fitness of cells expressing the mutant protein, reduced neurite length also means that these cells will show reduced connections with other neurons. One potential pathogenic mechanism is that neurons located in regions of relatively high LRRK2 expression (cortex, striatum, and hippocampus) may show reduced connections with nigral neurons, leading to reduced viability of these neurons. Therefore, dopaminergic neuronal dysfunction triggered by mutant LRRK2 might include both cell autonomous and non-cell autonomous mechanisms.
These ideas are currently difficult to test since transgenic mice overexpressing mutant forms of LRRK2 appear to lack the main hallmark of PD, namely nigral cell loss, (81, 82) although these models do show impaired functioning of the dopaminergic system and axonal pathology. (82) One way to address these issues is to use techniques leading to regionspecific overexpression, for instance by testing animals expressing mutant forms of LRRK2 in the striatum compared to animals expressing mutant LRRK2 in the substantia nigra.
From cell culture models the kinase activity of LRRK2 appears to play a role in toxicity. (37, 41, 83) These models are based on transient, high-level overexpression of LRRK2 and so may not be fully reflective of mechanisms in vivo, but they show that kinase-dead versions of LRRK2 are relatively innocuous compared to kinase-active mutants. There are at least two possible, non-mutually exclusive, interpretations of these observations (Fig. 2) . One is that LRRK2 mutants are kinase-activating when expressed in cells and therefore kinase-dead versions cannot be hyperactive. As a second possibility, if the kinase is a negative regulator of the GTPase domain, its kinase-dead versions would not switch off the ROC/GTPase domain and thus maintain the protein in a highaffinity state (GTP-bound) prolonging signaling. Is the toxic effect of LRRK2 related to normal function? At the time of writing, detailed phenotyping of LRRK2-knockout mice has not been reported, but mention of such animals as part of other studies (39, 72) suggests that the animals do not have a clear parkinsonian phenotype, arguing against a simple dominant-negative mechanism. In C. elegans, lrk-1 (the sole worm homolog of LRRK1 and LRRK2) knockout shows a neuronal polarity phenotype with no overt cell loss (84) ; however, the lrk-1 knockout does enhance sensitivity to mitochondrial stressors and G2019S mutant LRRK2 has a loss of protective function. (85) Drosophila animals with disrupted dLRRK (the sole fly homolog) show enhanced sensitivity to oxidative stress (86) and flies overexpressing mutant proteins show the same, (44) again supporting the idea that mutations may mimic loss of function. Clearly, identification of signaling pathways related to mutant LRRK2 will require use of several such model systems (for a more detailed review see Ref. (87) ).
Another consideration is that the pathogenic function of LRRK2 is unrelated to outputs normally triggered by the activity of the wild-type protein. If, as discussed above, multiple mutations result in LRRK2 being in a high-affinity state, then it is possible that the mutant protein gains novel interactors not normally available to wild-type LRRK2. Although this is speculative, we propose that screens for GTP-driven outputs should include dominant mutations.
In balance, these data suggest that LRRK2 mutations may work through either gain of detrimental function or loss of a normal putatively protective function or, potentially, through both. Although some work from in vitro models suggests that kinase activity is important, these results are very preliminary until robust phenotypes are seen in animal models. Only at such a point can we begin to tease apart how LRRK2 works from where LRRK2 mutations have damaging effects.
a-Synuclein is a toxic protein
As discussed above, one of the key pathologic events in PD and related disorders is the deposition of SNCA into Lewy bodies. Since this discovery, the question as to whether these protein inclusion bodies are themselves toxic or whether they are the end result of a neuroprotective mechanism has been the subject of debate. Because SNCA pathogenic mechanisms have been the subject of numerous reviews, only a brief outline of the main questions will be given here.
As well as likely being important in normal function, the structural flexibility of SNCA also underlines a tendency of SNCA to aggregate into b-sheet-like structures. (88) SNCA is aggregated into fibrillar forms in Lewy bodies, (89) suggesting that the in vitro behavior of the protein is related to the pathologic forms. However, several lines of evidence suggest that the fibrils themselves are not the toxic species and that intermediates along the aggregation pathway or oligomers are more likely to be detrimental to cells. The A30P and A53T clinical mutant forms of SNCA both promote the formation of oligomeric protofibrils, but only A53T robustly promotes the formation of b-pleated structures in vitro. (90) (91) (92) (93) (94) A recent study using structure-based design to create variants of SNCA that break its propensity to form b-sheets, found that neurotoxicity of SNCA could be correlated with the enhanced formation of soluble oligomers. (95) Collectively, these results show that while SNCA can be considered a toxic protein, the details of the precise toxic species are not fully defined. (96) Despite a great deal of work being performed in this area, why partially aggregated forms of SNCA are toxic to neurons is unclear. Clues from a variety of model systems suggest that the lipid binding capacity of the protein is important in some way, perhaps because SNCA can interfere with vesicle transport. (97, 98) Two things about the toxic effects of SNCA are clear. First, the expression of SNCA is almost entirely neuronal and thus cell-autonomous mechanisms are more likely although some recent results suggest that the protein could transfer between cells. (99) Second, wild-type SNCA has the potential to be detrimental. This last point is supported by human genetics, (15) (16) (17) (18) (19) but also by cell (100) and animal (101) (102) (103) (104) experimental model systems. The difference between mutant and wild-type protein is therefore quantitative, not qualitative, with SNCA toxicity correlating to an excess of an inherent property. Tau is also a toxic protein. Overexpression of mutated versions associated with frontotemporal dementia and parkinsonism causes neuronal damage in animal models, although formation of tangles per se is not always required to kill neurons. (105, 106) Importantly, transient expression of human wild-type tau in the substantia nigra causes dopaminergic cell loss and behavioral changes in rats. (107) Therefore, there is experimental evidence to support the idea that an exaggerated normal function of tau can damage the target neurons in PD. We can therefore suggest that a more modest increase of tau protein might sensitize the same neurons to a slower toxic event, driven by other detrimental proteins. In this context, it is interesting that tau is required for the toxic effects of aggregating amyloid protein. (108, 109) What is the relationship between LRRK2 and a-synuclein? And with tau?
Most LRRK2 cases have SNCA-positive Lewy bodies. We recently counted that 14/24 (60%) of LRRK2 cases reported had Lewy body pathology. (20) As well as strengthening the link between LRRK2 and sporadic PD, this result implies a relationship between LRRK2 and SNCA. Because SNCA in Lewy bodies is present in fibrillar structures, (96) we might infer that LRRK2 can promote the aggregation or deposition of SNCA, i.e., that LRRK2 is a director and SNCA is an actor in PD pathogenesis.
The manner in which LRRK2 may direct SNCA aggregation is unclear. Some early work showing the presence of LRRK2 in Lewy bodies suggested that both proteins may interact physically. However, only about a third of these structures were labeled, and not all LRRK2 antibodies show this pattern of staining. (75, 110) Therefore, LRRK2 does not seem to be a major protein deposited in PD, although some LRRK2 cases have unusual protein deposits. (69) A recent report (48) has proposed that LRRK2 controls phosphorylation of SNCA at serine 129, although the kinetics are very slow and it is unlikely to be a direct effect. (49) Other kinases, such as G protein-coupled receptor kinases (111, 112) and polo-like kinase type 2, (113) have also been shown to be critical for phosphorylation of SNCA in vivo. Therefore, an important issue will be to determine the relative contribution of LRRK2 to the control of the phosphorylation state of SNCA compared to these kinases. Overall, these data support the notion that LRRK2 may direct SNCA aggregation through a multi-step process rather than via direct interaction. What stops us making a simple diagram with one pathway from LRRK2 to SNCA are the LRRK2-positive, Lewy bodynegative cases. LRRK2 cases without Lewy bodies split approximately evenly between two additional pathologies. Some cases show tau-positive lesions of various types and some (114) may have inclusions of TAR DNA-binding protein 43 (TDP43), another protein deposited in the frontotemporal dementia spectrum disorders. This leads to one model that states that LRRK2 can work effectively through SNCA or tau or other aggregating proteins. If we extend this, we can suggest that LRRK2 is ''upstream'' of several events involving protein deposition and cell death, a Rosetta stone argument. However, there is a final group of LRRK2 patients without any pathology of specific protein aggregation and ''pure'' nigral cell loss. (69, 115) The apparent muteness of these cases speaks to another idea: that LRRK2 can cause cell death without tau or synuclein. Given that the clinical picture of LRRK2 cases is relatively consistent even though pathologies are variable, (20) this suggests that these two outcomes are independent. What complicates this argument is that we do not definitively know that deposition to form a Lewy body (or a tangle) is a required event in any neurodegenerative disease.
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To take one example, although mice treated with the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) do not form Lewy bodies, SNCA knockouts show less MPTPinduced neuronal cell death. (116) This suggests that SNCA can contribute to some toxic events without forming deposits. Furthermore, SNCA can promote tau phosphorylation, without full-blown tangles. (117) Therefore LRRK2 may still direct its pathologic effects through SNCA or tau in the absence of depositions of these proteins. Figure 3 outlines this framework for thinking about PD, but how could we test such models? It is critical to distinguish necessity from sufficiency for both SNCA and tau in mediating the toxic effects of LRRK2. For example, a way to test for the requirement of LRRK2 in tau or SNCA toxicity is to test animal models of tau or SNCA in animals not expressing LRRK2. Also, to say that LRRK2 is upstream of SNCA or tau, we need to show that LRRK2 is not regulated by either. 
Conclusion
In conclusion, recent advances in SNCA and LRRK2 research are refining our framework of thinking about how these genes cause disease. Specifically, LRRK2 is emerging as a molecule containing several elements of an intramolecular signaling cascade and the relationship between various forms of SNCA and toxicity is further delineated. Issues that require further clarification are the continued characterization of the intramolecular mechanisms of LRRK2 as well as the identification of the cellular pathways that normal and mutant LRRK2 impact. For SNCA, outstanding issues are the further delineation of the precise toxic species as well as the mechanism whereby toxicity is conferred. Finally, the cellular relationship between LRRK2, SNCA, and tau is a critical question as it may be the basis for developing diseasemodifying therapies in both familial and sporadic PD. Modeling the relationship between LRRK2, a-synuclein, and tau in PD pathogenic processes. A proposed relationship between LRRK2, which is upstream, and a-synuclein, which is downstream, leading to Parkinson's disease. Note that both a-synuclein and tau are also genetic risk factors for sporadic PD. Arrow thickness correlates with the strength of the process.
